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Purpose
We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-
cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib
monotherapy in patients with non-small cell lung cancer (NSCLC). Here, we report on a post
hoc subgroup analysis of that study assessing the demographics and disposition of the 
Korean patient subgroup, and comparing the tolerability of PC/G and gefitinib monotherapy
and the tumor response with respect to epidermal growth factor receptor (EGFR) status.
Materials and Methods
Patients, who were ! 18 years, chemonaïve, Korean, light ex-smokers/never-smokers with
advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. Treat-
ment-emergent adverse events (TEAEs) were graded, and tumor response was measured
as change in lesion sum from baseline at best response. The study was registered with Clin-
icalTrials.gov, NCT01017874.
Results
Overall, 111 Korean patients were treated (PC/G, 51; gefitinib, 60). Between-arm charac-
teristics were balanced and similar to those of the overall population. Treatment discontin-
uations due to adverse events were low (PC/G: 1, 2.0%; gefitinib: 7, 11.7%). Overall, 92
patients (82.9%) reported ! 1 TEAE (PC/G, 44; gefitinib, 48); few patients (PC/G, 16; gefi-
tinib, 7) reported severe TEAEs; the most frequent was neutropenia (PC/G arm) and elevated
alanine aminotransferase (gefitinib arm). The lesion sum was decreased by PC/G treatment
in most patients, regardless of EGFR mutation status, while gefitinib monotherapy reduced
the lesion sum in EGFR-positive patients but had no effect in EGFR-negative patients.
Conclusion
Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, 
regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit
from gefitinib monotherapy.
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Introduction
Lung cancer is the main cause of cancer-related deaths in
East Asia, accounting for one in four of all cancer-related
deaths [1]. In Korea, an estimated 16,990 deaths in 2014 were
caused by lung cancer, accounting for 22.7% of all cancer-
related deaths [2]. The current first-line standard of care for
advanced non-small cell lung cancer (NSCLC) is platinum-
based doublet chemotherapy [3], although inhibitors of the
epidermal growth factor receptor (EGFR) tyrosine kinase,
such as gefitinib, are recommended in patients harboring 
activating EGFR mutations [4-6]. The phase 3 Iressa Pan-Asia
Study (IPASS), which compared gefitinib monotherapy with
combination chemotherapy as first-line therapy in East Asian
patients, reported significantly longer progression-free sur-
vival (PFS) in patients who had EGFR mutations and were
treated with gefitinib [7]. A subsequent phase 2 trial, in
which combination chemotherapy followed by gefitinib or
pemetrexed maintenance therapy was administered in East
Asian patients with unknown EGFR status, reported longer
PFS in patients receiving gefitinib than those receiving peme-
trexed [8]. These findings may be attributed to the high fre-
quency of EGFR mutations in East Asian patients with
NSCLC [5,7,8].
The current randomized, open-label, phase 3 trial was 
designed for comparison of pemetrexed-cisplatin (PC) dou-
blet chemotherapy followed by gefitinib maintenance ther-
apy (PC/G) with gefitinib monotherapy in East Asian
patients with NSCLC and unknown EGFR mutation status
[9]. In the overall study population, there was no significant
difference in PFS between treatment arms [9]. However,
treatment response may differ in patients from various 
regions of East Asia or those with EGFR mutations that were
not evident from the primary analysis. To further assess 
potential differences in treatment response in the East Asian
population, we conducted a post hoc descriptive subgroup
analysis of Korean patients from this phase 3 trial. The 
Korean subgroup comprised the largest proportion of 
patients in the original study. The aims of the subgroup
analysis were to assess demographics and disposition of the
Korean patients randomized in the study, compare the tol-
erability of PC/G therapy with gefitinib monotherapy in this
subgroup, and assess the tumor response with respect to
EGFR status for each treatment arm.
Materials and Methods
This study was a post hoc subgroup analysis of data from a
randomized, open-label, phase 3 clinical trial (NCT0101
7874). Findings for the primary objective, which was to com-
pare PFS in patients treated with PC/G with those treated
with gefitinib monotherapy, were reported previously by
Yang et al. [9]. The study was conducted in accordance with
Good Clinical Practice guidelines and the Declaration of
Helsinki; all patients provided informed consent. Patient 
eligibility criteria included age ! 18 years, chemonaïve, East
Asian, and light ex-smokers/never-smokers with advanced
NSCLC. Patients were assigned (1:1) to receive either PC/G
therapy (PC [P, 500 mg/m2; C, 75 mg/m2] for six 21-day 
induction cycles, then gefitinib [250 mg/day] maintenance
therapy) or gefitinib monotherapy (G [250 mg/day], admin-
istered until progression, discontinuation, or death). Treat-
ment-emergent adverse events (TEAEs; possibly drug-rela-
ted) and serious adverse events were classified according to
MedDRA (ver. 15.1) and graded. Safety analyses were per-
formed on the safety population, which included all patients
who received ! 1 dose of the study drug. Tumor response,
conducted on the tumor response-qualified population 
(patients with lesion measurements taken at baseline and at
least 1 other time point), was measured as change in lesion
sum from baseline at best response. Change in lesion sum
was determined as the change from baseline in the sum of
the largest diameter of each lesion (up to a maximum of 10
lesions per patient). Analysis of patient tissue was performed
retrospectively for EGFR mutations.
Results
1. Patient disposition
A total of 253 patients were enrolled in the phase 3 study,
120 of whom were enrolled in Korea (Fig. 1). Of the 120 
Korean patients enrolled in the study, 114 patients were ran-
domly assigned to treatment: 54 patients were assigned to
PC/G (3 of whom were not treated); 60 patients were 
assigned gefitinib monotherapy. Thirty-three patients in the
PC/G arm received gefitinib maintenance therapy and 28 
patients in the gefitinib arm received more than six cycles of
treatment.
2. Patient demographics
Baseline patient demographics were balanced between
arms and similar to those reported for the overall study pop-
ulation (Table 1) [9]. All Korean patients had adenocarci-
noma, most were never-smokers (93.9%), had stage IV
disease (91.2%), and had a Eastern Cooperative Oncology
Group (ECOG) performance status of 1 (57.0%) (Table 1).
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Fig. 1. Disposition of Korean patients with non-small cell lung cancer treated with PC/G or gefitinib monotherapy. PC/G,
pemetrexed-cisplatin/gefitinib.
Table 1. Baseline patient demographics for the Korean patient subgroup
PC/G (n=54) Gefitinib (n=60) Total (n=114) p-value
Sex
Male 10 (18.5) 13 (21.7) 23 (20.2) 0.816
Female 44 (81.5) 47 (78.3) 91 (79.8)
Age (yr)
Mean (range) 59.43 (30.7-80.7) 62.16 (30.5-79.2) 60.87 (30.5-80.7) 0.161
< 65 35 (64.8) 36 (60.0) 71 (62.3) 0.699
! 65 19 (35.2) 24 (40.0) 43 (37.7)
Smoking status
Never-smoker 52 (96.3) 55 (91.7) 107 (93.9) 0.443
Light ex-smoker 2 (3.7) 5 (8.3) 7 (6.1)
Stage of disease
IIIB 4 (7.4) 6 (10.0) 10 (8.8) 0.746
IV 50 (92.6) 54 (90.0) 104 (91.2)
ECOG performance status
0 24 (44.4) 25 (41.7) 49 (43.0) 0.850
1 30 (55.6) 35 (58.3) 65 (57.0)
EGFR mutation status
Patients who provided samples 20 (37.0) 20 (33.3) 40 (35.1) -
EGFR mutated 4 (7.4) 8 (13.3) 12 (10.5)
EGFR not mutated 3 (5.6) 5 (8.3) 8 (7.0)
EGFR unknown 13 (24.1) 7 (11.7) 20 (17.5)
Values are presented as number (%) unless otherwise indicated. PC/G, pemetrexed-cisplatin/gefitinib; ECOG, Eastern 
Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
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3. Treatment duration
The median number of treatment cycles completed overall
was 7.0 and 6.0 for PC/G and gefitinib monotherapy, respec-
tively. The median number of treatment cycles was 6.0 for
both treatment arms during the induction period, and 4.0
and 7.5 for PC/G and gefitinib monotherapy, respectively,
during the maintenance period.
4. Response to therapy by EGFR status
The change in lesion sum from baseline was calculable for
47 patients in the PC/G arm and 53 patients in the gefitinib
arm. Lesion sum was reduced by treatment with PC/G in
the majority of Korean patients with NSCLC, regardless of
EGFR mutation status (Figs. 2A and 3A). In this selected pop-
ulation, lesion sum was reduced by gefitinib monotherapy
in the subgroup of Korean patients who were confirmed as
EGFR positive (n=8) (Figs. 2B and 3B). In contrast, gefitinib
monotherapy had no positive effect on lesion sum in the sub-
group of Korean patients who were EGFR negative (n=3)
(Figs. 2B and 3B).
5. Adverse events
Overall, 92 of 111 patients (82.9%) reported at least 1 TEAE
during treatment. Treatment discontinuation due to adverse
events (AEs) was low (PC/G, 1/51 [2.0%]; gefitinib, 7/60
[11.7%]). Few patients (PC/G, 16/51 [31.4%]; gefitinib, 7/60
[11.7%]) reported severe (grades 3-4) TEAEs during the over-
all treatment period; the most frequent was neutropenia in
the PC/G treatment arm and elevated alanine aminotrans-
ferase in the gefitinib treatment arm. No patients reported
grade 5 TEAEs (Table 2).
Table 2. Adverse events reported in at least 5% of Korean patients in either treatment arm during the induction phase of
treatment
Pemetrexed plus cisplatin (n=51)  Gefitinib (n=60)
Grades 1-2 Grades 3-4 Grades 1-2 Grades 3-4
Patients with ! 1 TEAE 30 (58.8) 13 (25.5) 41 (68.3) 7 (11.7)
Hematologic
Neutrophils/granulocytes 5 (9.8) 9 (17.6) 0 ( 0 (
Non-hematologic
ALT 0 ( 1 (2.0) 4 (6.7) 3 (5.0)
AST 0 ( 0 ( 5 (8.3) 2 (3.3)
Anorexia 15 (29.4) 1 (2.0) 3 (5.0) 0 (
Constipation 4 (7.8) 0 ( 0 ( 0 (
Diarrhoea 6 (11.8) 0 ( 12 (20.0) 2 (3.3)
Dry skin 0 ( 0 ( 8 (13.3) 0 (
Fatiguea) 3 (5.9) 1 (2.0) 6 (10.0) 0 (
Hair loss 5 (9.8) 0 ( 2 (3.3) 0 (
Hemorrhagea) 3 (5.9) 0 ( 2 (3.3) 0 (
Mucositisa) 1 (2.0) 0 ( 6 (10.0) 0 (
Nausea 24 (47.1) 2 (3.9) 4 (6.7) 0 (
Neuropathy, sensory 9 (17.6) 0 ( 2 (3.3) 0 (
Paina) 6 (11.8) 0 ( 2 (3.3) 1 (1.7)
Pruritus, itching 5 (9.8) 0 ( 18 (30.0) 0 (
Skin rasha) 3 (5.9) 0 ( 31 (51.7) 1 (1.7)
Vomiting 11 (21.6) 3 (5.9) 0 ( 0 (
Values are presented as number (%). ALT, alanine aminotransferase; AST, aspartate transaminase; TEAE, treatment-emergent
adverse event. Events are maximum grade per National Cancer Institute–Common Terminology Criteria for Adverse Events
(NCI-CTCAE, ver. 3.0). a)Fatigue, hemorrhage, mucositis, pain, and skin rash are combined from some specific CTCAE terms.
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Fig. 2. Waterfall plots of percent change in lesion sum from baseline at best response by epidermal growth factor receptor
(EGFR) status in Korean patients treated with pemetrexed-cisplatin/gefitinib (A) and gefitinib monotherapy (B). 
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Fig. 3. Spider plots of percent change in lesion sum from baseline at best response by epidermal growth factor receptor
(EGFR) status in Korean patients treated with pemetrexed-cisplatin/gefitinib (A) and gefitinib monotherapy (B). 
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Conclusion
Patient demographics and AEs in Korean patients with
NSCLC were similar to those reported in the overall study
population [9]. A slightly higher proportion of Korean 
patients experienced grades 3-4 hematologic TEAEs follow-
ing PC/G treatment compared with the overall population,
but, overall, both PC/G and gefitinib monotherapy were
well tolerated in Korean patients with NSCLC. Although a
limited number of samples were available for EGFR testing,
post hoc analysis of tumor response based on EGFR mutation
status showed that PC/G treatment consistently reduced 
lesion sum in patients with and without EGFR mutations, but
gefitinib monotherapy had no effect in patients with EGFR
wild-type. The findings of this Korean patient subgroup
analysis confirmed that PC/G and gefitinib monotherapy
showed favorable tolerability in patients with advanced
NSCLC; however, such patients with EGFR wild-type may
not benefit from gefitinib monotherapy.
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